Peptide Comparison
Semaglutide vs CagriSema
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Semaglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Semaglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Semaglutide | CagriSema | |
|---|---|---|
| Class | GLP-1 receptor agonist | Amylin + GLP-1 combination |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion [1][2] | Dual amylin + GLP-1 receptor agonism |
| Route | SC injection / Oral | SC injection |
| Half-life | ~7 days | ~7 days |
| Dosage (research) | 0.25 mg SC weekly (Wegovy/Ozempic label starting dose, escalate monthly to label max 2.4 mg weekly per STEP-1 protocol) [1][2][3]; oral 3 mg daily Rybelsus starting dose (target 14 mg daily) | 2.4 mg / 2.4 mg SC weekly |
| Evidence tier | FDA-Approved | Phase 3 |
| Research depth | 624 indexed | 113 indexed |
| Availability | Prescription | Investigational |
| Reported risks | Nausea; vomiting; constipation; pancreatitis; gallbladder disease; thyroid C-cell tumor warning [1][2] | GI effects; Phase 3 REDEFINE mixed results |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Semaglutide or CagriSema?
Semaglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Semaglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Semaglutide and CagriSema?
Semaglutide is classed as GLP-1 receptor agonist; CagriSema is classed as Amylin + GLP-1 combination. Reported mechanism: Semaglutide, GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion; CagriSema, Dual amylin + GLP-1 receptor agonism. Reported half-life: Semaglutide, ~7 days; CagriSema, ~7 days. Routes in published studies: Semaglutide, SC injection / Oral; CagriSema, SC injection.
Which has stronger evidence, Semaglutide or CagriSema?
Semaglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semaglutide is graded FDA-Approved, with 104 cited sources on its reference page and 624 indexed studies. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies.
Which is more accessible, Semaglutide or CagriSema?
Semaglutide is FDA-approved and CagriSema is not. Catalog status: Semaglutide, Prescription; CagriSema, Investigational.
Are Semaglutide and CagriSema ever combined?
Semaglutide and CagriSema appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…